Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

CRT 2026: Key takeaways for interventional cardiologists
CRT studies shed new light on many topics, including long-term TAVR outcomes, radiation protection and advanced interventional techniques.
FDA clears intravascular device billed as ‘world’s smallest camera’ as physicians share new data
The new device, which provides users with real-time images in full color, is now approved by the FDA to be used in the peripheral vasculature. Meanwhile, first-in-human data published in Stroke explored its potential in the cerebral vasculature.
Shortage of cardiac amyloidosis radiotracers should ease in late March
However, the regular supply of these imaging radiotracers may not be back online for another few months.
Cardiology now has more than 200 FDA-cleared AI algorithms
Cardiology is No. 2 behind radiology when it comes to FDA-cleared AI algorithms. Neurology, meanwhile, is a distant No. 3.
FDA clears AI-enabled cardiac MR planning technology from Philips
The new SmartHeart technology automates 14 cardiac views in less than 30 seconds. It was designed to increase productivity and bring more consistency to cardiology and radiology departments.

The HeartBeam AIMIGo device is approximately the size of a credit card and uses the company’s patented 3D vectorelectrocardiography (3D VECG) technology to capture signals from three different projections and deliver a synthesized 12-lead ECG.

ECG market keeps evolving thanks to AI, home monitoring and Epic integration

For years, the ECG market was relatively static. According to a new report, however, things are rapidly changing.

warning safety alert recall healthcare issue

Safety update: New recommendations for managing patients with high-risk defibrillation leads

HRS has shared an updated guidance on managing Boston Scientific defibrillation leads at risk of experiencing a significant malfunction. The issue, first reported in July 2025, is believed to impact approximately 350,000 leads still being used today.

Boston EP Party: Medtech companies share new electrophysiology data at AF Symposium 2026

AF Symposium 2026 in Boston included new data from some of the biggest names in electrophysiology. Johnson & Johnson MedTech, Abbott, Atraverse Medical, Field Medical, Pulse Biosciences, Argá Medtech SA and CardioFocus were just some of the medtech companies at the heart of late-breaking presentations.

startup business healthcare medtech heart

Radiologists and cardiologists at odds over who handles heart imaging interpretations

Many cardiologists overseas contend they should be the ones reading these exams, citing radiologists’ lack of clinical context as a key factor, especially for remote reads.

Interventional cardiologists take on angiography-derived physiology in new expert opinion

ADP offers care teams multiple benefits not seen with traditional wire-based physiologic assessments. A roundtable of 17 expert clinicians discussed the topic at length, and their findings were used to develop a new manuscript published in JSCAI.

The Impella RP with SmartAssist. Image courtesy of Johnson & Johnson MedTech.

FDA warns that Johnson & Johnson heart pump sensors may malfunction—22 injuries reported

There is a risk of users making adjustments during treatment that are unnecessary. The FDA is still evaluating the issue at this time.

artificial intelligence money finance acquisition

Medtronic to acquire AI-enabled FFR specialists CathWorks for up to $585M

Medtronic has held a minority investment in CathWorks for several years, and the two organizations entered into a co-promotion agreement in 2022. Once finalized, the move will increase Medtronic's presence in the cath lab.

New data from the Phase 3 RAPID clinical trial of etripamil, an investigational calcium channel blocker nasal spray, showed positive results in converting paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm in the at-home setting. The presentation was featured during a late-breaking clinical trials session at the American Heart Association (AHA) 2022 Scientific Sessions. #AHA22

Nasal spray for paroxysmal supraventricular tachycardia enters US market

New drug allows patients to self-treat PSVT. About 2 million people in the U.S. have been diagnosed with condition.

Cardiac Imaging

CRT 2026: Key takeaways for interventional cardiologists

FDA clears intravascular device billed as ‘world’s smallest camera’ as physicians share new data

Shortage of cardiac amyloidosis radiotracers should ease in late March

Cardiology now has more than 200 FDA-cleared AI algorithms

FDA clears AI-enabled cardiac MR planning technology from Philips